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Response to letter of Dr Zanen re:
paper by Milanowski et al. (Respir
Med 1999; 93: 245±251)We thank Dr Zanen for his reasoned statistical comments
on the studies (1,2). However, the aim of the two studies
was to demonstrate therapeutic equivalence between the
BDP-CFC and BDP-HFA inhalers based on meaningful
clinical dierences in everyday practice. Unfortunately, Dr
Zanen’s assumption that equivalence was based on a lack of
statistically significant dierences between the two prepara-
tions is incorrect given that the conclusions of equivalence
were derived from comparisons of confidence intervals for
the between-treatment dierence and an acceptable range
considered to be clinically equivalent.
The significant and equivalent improvements in lung
function and asthma symptoms seen with both BDP-CFC
and BDP-HFA in these studies are entirely consistent with
the literature on similar inhaled steroid studies. Minor
numerical dierences in lung function indices and standard
deviations between populations are unlikely to matter in
clinical practice, as has been borne out by successful
transfer of asthma patients from the BPD-CFC to the
BDP-HFA inhaler on a 1:1 dose basis since introduction of
the latter product to the market in Ireland 18 months ago.
We reiterate our belief that the sample sizes chosen in
these studies were based on clinically relevant dierences
and that the products are indeed equivalent in both
meaningful statistical terms and in clinical practice.
V. L. PERRIN, D. W. FAKES AND
D. UNDERWOOD
Norton Healthcare Ltd and Statwood Partnership
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Inhaled beclomethasone (BDP) with
non-CFC propellant (HFA-134a) is
equivalent to BDP-CFC for the
treatment of asthma: Milanowski
et al. (Respir Med 1999; 93: 245±251)I read with interest the paper from Milanowski et al. on the
equivalence of BDP-HFA to BDP-CFC. This is based on
two studies, one low dose (400 mcg day71 BDP) and one
high dose (2000 mcg day71). The results of these studies I
think should be viewed with caution but open up some
interesting areas of debate.
The statistical analysis for both studies was based on
testing for dierence. This was defined as a dierence in
mean pre-dose FEV1 of 402 l. The results clearly show
that the 90% confidence interval for the high dose study
(7034–05) lies outside +02 l. Similarly for the low dose
study the 90% confidence interval is (7014–035), again
lying outside the upper end of the pre-defined +02 l.
It is stated that the total number of patients needed to
detect a statistical dierence with 90% power using 90%
confidence intervals was 100. The standard deviation for
FEV1 in both studies was around 08 l. To detect
equivalence or dierence, based on these assumptions, the
total number of patients needed would be 275 and 338 per
treatment group respectively, greatly in excess of 100. It
would therefore appear that these studies are both under-
powered and inconclusive. Consequently the interpretation
by Milanowski et al. that BDP-CFC and BDP-HFA
(Norton Healthcare Ltd, U.K.) are clinically and statisti-
cally equivalent should be viewed with caution.
The dosing schedule of qds dosing is not in line with the
British Asthma Guidelines and would have led to poor
compliance in some subjects. The rationale behind this
schedule needs to be justified. In the high dose study a very
wide-ranging group of patients (taking 800–2000 mcg day
BDP71) were randomized to 2000 mcg of either BDP-HFA
or BDP-CFC patients. This wide variability may account
for the large confidence intervals seen in this study, but
underlies the need to conduct robustly designed ecacy and
safety studies as well as dose response studies.
The study also considers safety, as measured by adverse
events and am plasma cortisol. Morning plasma cortisol is
a very variable measure and studies using 24 h urinary free
cortisol would be a more helpful measure to define any
clinically relevant dierence between the two formulations.
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to interpret and do not provide sucient evidence to
support the conclusion the two formulations have equiva-
lent tolerability.
In their discussion Milanowski and colleagues question
the design of clinical studies of other HFA-BDP prepara-
tions. There is currently only one HFA-BDP preparation
(Qvar, 3M Pharmaceuticals) licenced in the U.K. There are
many robustly designed studies that have been conducted
using this formulation in both symptomatic and well
controlled, steroid requiring and steroid naı¨ve patients,
for both short (6–12 week) and long term (12 months)
(1,2,3,4,5). There is also a well designed dose response study
which compares CFC-BDP and HFA-BDP in a direct mcg
for mcg comparison (6). All these studies show that patients
can be adequately controlled on around half the dose of
CFC-BDP without loss of asthma control. The comments
by Milanowski et al. on the risk of loss of asthma control in
well controlled patients and unwanted systemic eects when
switched to Qvar are thus incorrect and unwarranted.
In contrast to this, Milanowski correctly reports that
there is one study which indicates that the HFA-BDP
formulation from 3M Pharmaceuticals is equivalent to
CFC-BDP (7). This study was only designed to provide an
initial indication of absolute ecacy and was not ade-
quately powered to allow formal conclusions to be drawn
on the relative potency of Qvar compared with CFC-BDP.
Careful reading of the paper shows that the patients in this
study were well controlled, the average baseline FEV1 as a
percent of predicted being 805%, near their lung function
ceiling. For this group of patients it is likely that neither
formulation of beclomethasone would show a large increase
in pulmonary function but would just demonstrate that
control of asthma symptoms could be maintained. However
this highlights the point that interpretation of the outcome
of a single study in extending to a wider treatment
population should be viewed carefully until supported by
other robustly designed trials.
In conclusion, I believe that data presented by Mila-
nowski and colleagues should be viewed with extreme
caution. The data presented, both statistically and clini-
cally, do not support the claims made of clinical equiva-
lence. More rigorously designed studies on this formulation
should be reported before a conclusion of clinical equiva-
lence can be made.
J. G. AYRES
Department of Respiratory Medicine,
Birmingham Heartlands Hospital, U.K.
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Inhaled beclomethasone (BDP) with
non-CFC propellant (HFA 134a) is
equivalent to BDP-CFC for the
treatment of asthma (Respir Med 1999;
93: 245±251)Milanowski et al. (1) imply that CFC and HFA-propellant
formulated beclomethasone dipropionate (BDP) were
equipotent in their eects on lung function and asthma
symptoms in subjects with sub-optimally controlled asth-
ma. What they have in fact shown is that low and high
doses of both formulations of BDP produced similar
changes in spirometric values and symptoms suggesting
that the response had reached a plateau with the lower
dose. A more clear cut dose–response relationship may
have been seen with markers of the systemic eects of
inhaled BDP and it is unfortunate that the data on 0900 h
cortisol concentrations before and after treatment was not
presented more fully. The figure illustrating abnormal
cortisol concentrations during the high dose study shows
that 13 subjects with normal cortisol concentrations at
baseline developed low concentrations during treatment
with BDP-HFA compared to two subjects with BDP-CFC.
This suggests than BDP-HFA is more potent and/or more
